과립구 콜로니 자극 인자(G-CSF) 시장 : 세계 예측(2026-2032년)

The Granulocyte-Colony Stimulating Factor Market is projected to grow by USD 7.05 billion at a CAGR of 9.69% by 2032.

Granulocyte-Colony Stimulating Factor: Executive Overview

Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic growth factor used primarily to reduce or manage chemotherapy-associated neutropenia, support stem-cell mobilization, and treat selected severe chronic neutropenia conditions. The therapeutic landscape includes short-acting and long-acting approaches, with treatment selection shaped by chemotherapy regimen, infection risk, patient characteristics, care setting, and local clinical guidance. Biosimilar availability, administration convenience, and reimbursement policy are important factors influencing access and prescribing decisions.

Clinical Standardization and Biosimilar Competition Are Reshaping Care

The landscape is shifting toward more protocol-driven prevention of febrile neutropenia, wider use of risk-adapted supportive care, and greater emphasis on outpatient administration. Biosimilars are increasing competitive pressure around established biologic therapies while requiring continued attention to interchangeability rules, pharmacovigilance, clinician confidence, and patient communication. Longer-acting formulations and delivery options can reduce injection burden, but adoption depends on evidence, affordability, logistics, and alignment with chemotherapy schedules.

Artificial Intelligence Is Strengthening Risk Stratification and Operations

Artificial intelligence can support G-CSF utilization by identifying patients at elevated risk of neutropenia, integrating laboratory trends with treatment histories, and helping care teams prioritize monitoring. Predictive tools may also improve scheduling, dose-timing workflows, adverse-event surveillance, and identification of patients who need escalation or follow-up. These applications require representative clinical data, transparent validation, human oversight, and safeguards against bias, because treatment decisions remain dependent on clinical judgment and approved indications.

Regional Insights: Access, Guidelines, and Delivery Models Differ

North America combines mature oncology infrastructure with strong attention to guideline adherence, payer controls, and biosimilar adoption. Europe emphasizes health-technology assessment, national reimbursement decisions, and coordinated regulatory standards, while variation among countries affects uptake. Asia-Pacific includes advanced markets with established supportive-care pathways alongside rapidly expanding systems where affordability and distribution remain central. Latin America is shaped by public-sector procurement, uneven access, and private-public differences. The Middle East is investing in specialized oncology capacity, with access varying by national health-system resources. Africa faces substantial disparities in diagnosis, cancer treatment availability, cold-chain reliability, and continuity of supportive care.

Group Insights: Economic and Policy Blocs Shape Adoption

ASEAN markets show varied regulatory maturity and purchasing capacity, making regional harmonization and supply reliability important. BRICS members span advanced and developing oncology systems, with domestic manufacturing, public procurement, and affordability influencing access. The European Union benefits from shared regulatory principles but retains national differences in reimbursement and clinical implementation. G7 countries generally have robust oncology infrastructure, although cost containment and equitable access remain priorities. GCC systems are expanding specialist capacity and may adopt centralized procurement and international clinical standards. NATO members show broad healthcare diversity, so alliance membership does not translate into uniform treatment access or policy.

Country Insights: National Systems Determine Clinical Reach

Australia and Canada emphasize evidence-based reimbursement within geographically dispersed systems. Brazil and Mexico face regional access differences and a meaningful role for public procurement. China is strengthening oncology capacity while balancing affordability, regulatory development, and domestic supply objectives. France, Germany, Italy, Spain, and the United Kingdom apply structured clinical and reimbursement frameworks, with differences in assessment, tendering, and delivery pathways. India combines major specialist centers with uneven access across states and income groups. Japan and South Korea have advanced clinical infrastructure and aging-population needs, alongside detailed reimbursement and regulatory requirements. Russia's access is influenced by domestic production, procurement policy, and healthcare-system conditions. The United States has broad treatment availability but significant payer, site-of-care, and affordability variation.

Prioritize Evidence, Resilience, and Patient-Centered Delivery

Industry leaders should align product development and commercialization with clearly defined neutropenia-risk populations, comparative evidence, and real-world outcomes. Strengthening biosimilar confidence requires transparent analytical and clinical evidence, reliable pharmacovigilance, and education for prescribers and patients. Supply strategies should diversify manufacturing and cold-chain pathways, while market access plans should address public procurement, reimbursement evidence, and regional inequities. Digital and AI-enabled tools should be deployed with validated workflows, cybersecurity controls, and clinician oversight. Patient support should focus on adherence, injection education, infection-warning awareness, and coordination between oncology centers and community care.

Methodology: Evidence-Based Synthesis of Clinical and Market-Access Drivers

This executive summary uses the defined G-CSF market scope and organizes findings across clinical use, formulation trends, biosimilar dynamics, policy, access, and healthcare delivery. Insights are derived from established clinical practice concepts, regulatory and reimbursement considerations, peer-reviewed evidence, and publicly documented healthcare-system characteristics. Regional, group, and country comparisons are qualitative; they do not represent market estimates, forecasts, shares, or rankings. Interpretation should be updated as guidelines, approvals, procurement rules, and safety evidence evolve.

Conclusion: G-CSF Access Will Depend on Value, Trust, and Execution

G-CSF remains an important supportive-care intervention in oncology and selected hematologic conditions. Future progress will be determined less by a single product attribute than by the combined effect of clinical evidence, biosimilar confidence, affordability, supply resilience, delivery convenience, and responsible use of data and AI. Organizations that connect innovation with guideline-based care and measurable patient outcomes will be better positioned to improve access across diverse health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Granulocyte-Colony Stimulating Factor Market, by Product Type

• 7.1. Introduction
• 7.2. Biosimilar
  • 7.2.1. Filgrastim Biosimilar
  • 7.2.2. Pegfilgrastim Biosimilar
• 7.3. Originator
  • 7.3.1. Filgrastim
  • 7.3.2. Lenograstim
  • 7.3.3. Pegfilgrastim

8. Granulocyte-Colony Stimulating Factor Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Subcutaneous

9. Granulocyte-Colony Stimulating Factor Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Granulocyte-Colony Stimulating Factor Market, by Application

• 10.1. Introduction
• 10.2. Chemotherapy Induced Neutropenia Prophylaxis
• 10.3. Severe Chronic Neutropenia Treatment
• 10.4. Stem Cell Mobilization

11. Granulocyte-Colony Stimulating Factor Market, by End User

• 11.1. Introduction
• 11.2. Homecare Settings
• 11.3. Hospitals
• 11.4. Oncology Clinics

12. Granulocyte-Colony Stimulating Factor Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Granulocyte-Colony Stimulating Factor Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Granulocyte-Colony Stimulating Factor Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Amgen Inc.
• 16.2. BIOCAD
• 16.3. Biocon
• 16.4. Celltrion, Inc.
• 16.5. Coherus BioSciences, Inc.
• 16.6. Dr. Reddy's Laboratories Ltd.
• 16.7. GlaxoSmithKline plc
• 16.8. Intas Pharmaceuticals Ltd.
• 16.9. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 16.10. Kyowa Kirin Co., Ltd.
• 16.11. Merck KGaA
• 16.12. Novartis AG
• 16.13. Pfizer Inc.
• 16.14. Sandoz International GmbH
• 16.15. Spectrum Pharmaceuticals, Inc.
• 16.16. STADA Arzneimittel AG
• 16.17. Teva Pharmaceutical Industries Ltd.
• 16.18. Viatris Inc.

17. Key Experts